Tai Sandi See

CIK: 0002009350

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (66.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LXEO

Lexeo Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

LXEO
Lexeo Therapeutics, Inc.
Nov 18, 2025
Sale(S)
Direct
386 shares at avg. $9.27$4K
LXEO
Lexeo Therapeutics, Inc.
Oct 17, 2025
Sale(S)
Direct
3.8K shares at avg. $8.94$34K
LXEO
Lexeo Therapeutics, Inc.
Oct 17, 2025
Sale(S)
Direct
44 shares at avg. $9.56$420.684
LXEO
Lexeo Therapeutics, Inc.
Oct 15, 2025
Award(A)
Direct
10.9K shares-
LXEO
Lexeo Therapeutics, Inc.
Aug 18, 2025
Sale(S)
Direct
382 shares at avg. $4.67$2K
LXEO
Lexeo Therapeutics, Inc.
May 16, 2025
Sale(S)
Direct
367 shares at avg. $2.77$1K
LXEO
Lexeo Therapeutics, Inc.
Mar 14, 2025
Award(A)
Direct
5.7K shares at avg. $2.61$15K
LXEO
Lexeo Therapeutics, Inc.
Feb 19, 2025
Sale(S)
Direct
1.5K shares at avg. $4.41$7K
LXEO
Lexeo Therapeutics, Inc.
Jan 7, 2025
Award(A)
Direct
38.8K shares-

		Type	Shares	Price		Ownership
Nov 18, 2025	LXEO Lexeo Therapeutics, Inc.	Sale(S)	386	$9.27	$3,578	Direct
Oct 17, 2025	LXEO Lexeo Therapeutics, Inc.	Sale(S)	3,844	$8.94	$34,346	Direct
Oct 17, 2025	LXEO Lexeo Therapeutics, Inc.	Sale(S)	44	$9.56	$421	Direct
Oct 15, 2025	LXEO Lexeo Therapeutics, Inc.	Award(A)	10,890	-	-	Direct
Aug 18, 2025	LXEO Lexeo Therapeutics, Inc.	Sale(S)	382	$4.67	$1,783	Direct
May 16, 2025	LXEO Lexeo Therapeutics, Inc.	Sale(S)	367	$2.77	$1,018	Direct
Mar 14, 2025	LXEO Lexeo Therapeutics, Inc.	Award(A)	5,720	$2.61	$14,929	Direct
Feb 19, 2025	LXEO Lexeo Therapeutics, Inc.	Sale(S)	1,486	$4.41	$6,558	Direct
Jan 7, 2025	LXEO Lexeo Therapeutics, Inc.	Award(A)	38,750	-	$0	Direct

1-9 of 9 transactions

About See Tai Sandi

See Tai Sandi (SEC CIK 0002009350) files insider reports with the SEC as Chief Development Officer of Lexeo Therapeutics, Inc. (LXEO).

Signal8 holds 7 ownership filings by See Tai Sandi, all Form 4s, filed between Jan 10, 2025 and Nov 20, 2025. Those filings report 9 transactions, from Jan 7, 2025 to Nov 18, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on See Tai Sandi's filings is in NEW YORK, NY.

Recent filings by See Tai Sandi

Nov 18, 2025: Open-market sale of LXEO shares (Form 4, code S).
Oct 17, 2025: Open-market sales of LXEO shares (2 lines, Form 4, code S).
Oct 15, 2025: Grant or award of LXEO shares (Form 4, code A).
Aug 18, 2025: Open-market sale of LXEO shares (Form 4, code S).
May 16, 2025: Open-market sale of LXEO shares (Form 4, code S).

Other insiders filing for Lexeo Therapeutics, Inc. (LXEO)

Tamayo Louis Edward, Chief Financial Officer
Bhalla Narinder Pal, Chief Medical Officer
Otero Jose Manuel, Chief Operating Officer
Townsend Richard Nolan, Chief Executive Officer
Altschuler Steven, Director
Agger Mette Kirstine, Director

How to read Form 4 transaction codes